Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020-Reference-Cited by-同舟云学术

Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020

Published:2022-12 Issue:6 Volume:7 Page:100593
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Paratore C.,Zichi C.,Audisio M.,Bungaro M.,Caglio A.,Di Liello R.,Gamba T.,Gargiulo P.,Mariniello A.,Reale M.L.,Perrone F.,Di Maio M.^ORCID

Funder

Janssen Pharmaceuticals

Roche

Merck Sharp and Dohme

Boehringer Ingelheim

Eisai

Bristol-Myers Squibb

Astellas Pharma US

Takeda Pharmaceutical Company

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference34 articles.

1. Subgroup analyses in reporting of phase III clinical trials in solid tumors;Zhang;J Clin Oncol,2015

2. Clinical trials: subgroup analyses in randomized trials--more rigour needed;Altman;Nat Rev Clin Oncol,2015

3. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials;Yusuf;JAMA,1991

4. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives;Brookes;Health Technol Assess,2001

5. Three simple rules to ensure reasonably credible subgroup analyses;Burke;BMJ,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020;JAMA Network Open;2024-03-28

2. Clinical data mining: challenges, opportunities, and recommendations for translational applications;Journal of Translational Medicine;2024-02-20

3. Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review;JNCI Cancer Spectrum;2023-10-31